A5024012524- Cutaneous Melanoma Detection and Management
- Melanoma and MAPK Pathways
- Cancer Immunotherapy and Biomarkers
- Immunotherapy and Immune Responses
- CAR-T cell therapy research
- Contact Dermatitis and Allergies
- Allergic Rhinitis and Sensitization
- Food Allergy and Anaphylaxis Research
- Ocular Oncology and Treatments
- Autoimmune Bullous Skin Diseases
- Urticaria and Related Conditions
- Nonmelanoma Skin Cancer Studies
- Sarcoma Diagnosis and Treatment
- Cancer and Skin Lesions
- Nail Diseases and Treatments
- Polyomavirus and related diseases
- Tumors and Oncological Cases
- Antenna Design and Analysis
- Drug-Induced Adverse Reactions
- Cutaneous lymphoproliferative disorders research
- Full-Duplex Wireless Communications
- Histiocytic Disorders and Treatments
- Occupational exposure and asthma
- Coagulation, Bradykinin, Polyphosphates, and Angioedema
- Dermatology and Skin Diseases
Saarland University
2016-2025
Universitätsklinikum des Saarlandes
2013-2024
TU Dresden
2022
LMU Klinikum
2020
Ludwig-Maximilians-Universität München
2020
Eastern Cooperative Oncology Group
2020
Institute of Dermatology
2018
Charité - Universitätsmedizin Berlin
2014
ENT and Allergy
2014
Medical University of Graz
2014
Abstract Background Preventive measures to decrease the frequency and intensity of anaphylactic events are essential provide optimal care for allergic patients. Aggravating factors may trigger or increase severity anaphylaxis therefore need be recognized avoided. Objective To identify prioritize associated with an increased risk developing severe anaphylaxis. Methods Data from Anaphylaxis Registry (122 centers in 11 European countries) were used logistic regression models considering...
Currently, there are no robust biomarkers that predict immunotherapy outcomes in metastatic melanoma. We sought to build multivariable predictive models for response and survival anti-programmed cell death protein 1 (anti-PD-1) monotherapy or combination with anticytotoxic T-cell lymphocyte-4 (ipilimumab [IPI]; anti-PD-1 ± IPI) by including routine clinical data available at the point of treatment initiation.One thousand six hundred forty-four patients melanoma treated IPI 16 centers from...
Food is one of the most common elicitors anaphylaxis, with an increasing incidence over recent years.
Abstract Background Anaphylaxis is the most severe manifestation of an IgE‐dependent allergy. Standardized acquired clinical data from large cohorts well‐defined cases are not available. The aim this study was to analyse symptom profile and risk factors anaphylaxis in a Central European cohort. Methods We patients Germany, Austria Switzerland who experienced allergic reaction defined by onset pulmonary and/or cardiovascular symptoms. were gained via online questionnaire 83 medical centres...
Background: Anaphylaxis is the most severe manifestation of a mast cell-dependent immediate reaction and may be fatal.According to data from Berlin region, its incidence 2-3 cases per 100 000 persons year.Methods: We evaluated anaphylaxis registry German-speaking countries for 2006-2013 protocols ADAC air rescue service 2010-2011 study triggers, clinical manifestations, treatment anaphylaxis.Results: The contained on 4141 patients, concerned 1123 patients.In registry, common triggers were...
Dermatofibrosarcoma protuberans (DFSP) is a rare cutaneous tumor. COL1A1-PDGFB gene fusion frequent in DFSP, rendering tumor cell proliferation and survival dependent on PDGFRβ (platelet-derived growth factor receptor β) signaling. This trial investigated imatinib as neoadjuvant treatment of including long-term follow-up.The primary endpoint this multicenter phase II was response; secondary endpoints were safety, relapse, response biomarkers. Patients with advanced or locally recurrent DFSP...
Abstract BACKGROUND: Systemic high‐dose interleukin‐2 (IL‐2) achieved long‐term survival in a subset of patients with advanced melanoma. The authors reported previously that intratumorally applied IL‐2 induced complete local responses all metastases >60% patients. objectives the current study were to confirm those results larger cohort and identify patient or regimen characteristics associated response. METHODS: Patients melanoma who had median 12 injectable received intratumoral...
Uveal melanoma (UM) is highly refractory to treatment with dismal prognosis in advanced stages. The value of the combined checkpoint blockade CTLA-4 and PD-1 inhibition metastatic UM currently unclear.Patients or unresectable treated ipilimumab combination a inhibitor were collected from 16 German skin cancer centers. Patient records 64 cases analyzed for response, progression-free survival (PFS), overall (OS), safety. Clinical parameters serum biomarkers associated OS response determined...
PURPOSE BRAF/MEK inhibition is a standard of care for patients with BRAF V600E/K–mutated metastatic melanoma. For less frequent mutations, however, efficacy data are limited. METHODS In the current study, 103 melanoma rare, activating non-V600E/K mutations that were treated either inhibitor (BRAFi), MEK (MEKi), or combination included. mutation, patient and disease characteristics, response, survival analyzed. RESULTS Fifty-eight tumors (56%) harbored non-E/K V600 38 (37%) non-V600 seven had...
// Jürgen C. Becker 1, 2, 15 , Eva Lorenz 3, 14 Selma Ugurel 2 Thomas K. Eigentler 4 Felix Kiecker 5 Claudia Pföhler 6 Ivonne Kellner 7 Friedegund Meier 8, 16 Katharina Kähler 9 Peter Mohr 10 Carola Berking 11 Gabriele Haas Christoph Helwig 12 Dina Oksen Dirk Schadendorf Lisa Mahnke 13 and Murtuza Bharmal 1 Translational Skin Cancer Research (TSCR), German Center (DFKZ) Partner Site Essen/Düsseldorf, Essen University Hospital, 45147, Essen, Germany Department of...
PD-1-based immune checkpoint inhibition (ICI) is the major backbone of current melanoma therapy. Tumor PD-L1 expression represents one few biomarkers predicting ICI therapy outcome. The objective present study was to systematically investigate whether type tumor tissue examined for has an impact on correlation with outcome.Pre-treatment collected within prospective DeCOG cohort ADOREG/TRIM (CA209-578; NCT05750511) between February 2014 and May 2020 from 448 consecutive patients who received...
Mucosal melanoma represents ~1% of all melanomas, frequently having a poor prognosis due to diagnosis at late stage disease. differs from cutaneous not only in terms poorer clinical outcome but also on the molecular level e.g. less BRAF and more frequent KIT mutations than melanomas. For majority mucosal melanomas oncogenic driver remain unknown.In our study, 75 tumor tissues patients diagnosed with were analyzed, applying targeted next generation sequencing panel covering 29 known...